Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 36 citing articles:

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Stéphanie Lheureux, Mihaela Cristea, Jeffrey P. Bruce, et al.
The Lancet (2021) Vol. 397, Iss. 10271, pp. 281-292
Open Access | Times Cited: 168
DNA damage induces p53-independent apoptosis through ribosome stalling
N. Boon, Rafaela A. Oliveira, Pierre-René Körner, et al.
Science (2024) Vol. 384, Iss. 6697, pp. 785-792
Closed Access | Times Cited: 36
Overcoming Chemotherapy Resistance in SCLC
Brett H. Herzog, Siddhartha Devarakonda, Ramaswamy Govindan
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 12, pp. 2002-2015
Open Access | Times Cited: 75
SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
Ukhyun Jo, Yasuhisa Murai, Sirisha Chakka, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 6
Open Access | Times Cited: 58
Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A Review
Kiyotaka Watanabe, Nobuhiko Seki
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 752-752
Open Access | Times Cited: 13
Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress
Junko Murai, Hongliang Zhang, Lőrinc Sándor Pongor, et al.
Cell Reports (2020) Vol. 30, Iss. 12, pp. 4137-4151.e6
Open Access | Times Cited: 68
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
C Winkler, Joshua Armenia, Gemma N. Jones, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 5, pp. 951-962
Open Access | Times Cited: 56
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Naoko Takebe, Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 14, pp. 3834-3844
Open Access | Times Cited: 54
A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers
Bingnan Zhang, Kavya Ramkumar, Robert J. Cardnell, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 10, pp. 1333-1340
Open Access | Times Cited: 39
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
Sophie E. Willis, C Winkler, Martine P. Roudier, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 12, pp. 1666-1676
Open Access | Times Cited: 35
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer
Daniela Scattolin, Alessandro Dal Maso, Alessandra Ferro, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102768-102768
Closed Access | Times Cited: 6
Structural and biochemical characterization of human Schlafen 5
Felix J. Metzner, Elisabeth Huber, Karl‐Peter Hopfner, et al.
Nucleic Acids Research (2021) Vol. 50, Iss. 2, pp. 1147-1161
Open Access | Times Cited: 31
SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
C Winkler, Matthew King, Julie Berthe, et al.
JCI Insight (2021) Vol. 6, Iss. 18
Open Access | Times Cited: 24
Schlafens Can Put Viruses to Sleep
Eui Tae Kim, Matthew D. Weitzman
Viruses (2022) Vol. 14, Iss. 2, pp. 442-442
Open Access | Times Cited: 19
Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors
Blessie Elizabeth Nelson, Funda Meric‐Bernstam
Annual Review of Medicine (2023) Vol. 75, Iss. 1, pp. 31-48
Closed Access | Times Cited: 10
Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines
A. V. Razumovskaya, M. O. Silkina, А. А. Полозников, et al.
Frontiers in Molecular Biosciences (2025) Vol. 12
Open Access
Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma
Takeaki Nakamura, Kanako C. Hatanaka, Y. Kawamoto, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 5
Open Access
Schlafens: Emerging Proteins in Cancer Cell Biology
Sarmad Al‐Marsoummi, Emilie E. Vomhof‐DeKrey, Marc D. Basson
Cells (2021) Vol. 10, Iss. 9, pp. 2238-2238
Open Access | Times Cited: 23
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
Ming Zhao, Timothy P. DiPeri, Maria Gabriela Raso, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 9
Death by ribosome
Anna Vind, Franklin L. Zhong, Simon Bekker‐Jensen
Trends in Cell Biology (2024)
Closed Access | Times Cited: 3
Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer
Victoria Tserpeli, Dimitra Stergiopoulou, Dora Londra, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 4-4
Open Access | Times Cited: 17
SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy
Ahmed Adham Raafat Elsayed, Sarmad Al‐Marsoummi, Emilie E. Vomhof‐DeKrey, et al.
Cancer Genomics & Proteomics (2022) Vol. 19, Iss. 3, pp. 328-338
Open Access | Times Cited: 12
Identifying gene expression patterns associated with drug-specific survival in cancer patients
Bridget Neary, Jie Zhou, Peng Qiu
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 16
Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets
Maciej Kaczorowski, Kris Ylaya, Małgorzata Chłopek, et al.
The American Journal of Surgical Pathology (2024) Vol. 48, Iss. 12, pp. 1512-1521
Closed Access | Times Cited: 2
Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication
Torin Waters, Kelli L. Goss, Stacia L. Koppenhafer, et al.
BMC Cancer (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top